Related Experiment Videos
Adequate primaquine for vivax malaria.
Scott Kitchener1, Peter Nasveld, Sonya Bennett
1Centre for Military and Veterans' Health, Herston, Australia.
Journal of Travel Medicine
|July 6, 2005
Summary
Primaquine treatment for vivax malaria prevents relapses. A higher dose of 30 mg daily is more effective than 22.5 mg, reducing relapse risk significantly.
Area of Science:
- Tropical Medicine
- Infectious Diseases
- Parasitology
Background:
- Primaquine is crucial for preventing vivax malaria relapses by targeting liver-stage parasites.
- Inadequate primaquine dosing correlates with an increased risk of malaria relapse.
Purpose of the Study:
- To compare the efficacy of two primaquine dosage regimens (22.5 mg vs. 30 mg daily) in preventing vivax malaria relapse.
- To evaluate the impact of primaquine dosage on relapse rates in a military population.
Main Methods:
- A retrospective analysis of 146 cases from the Australian Army Central Malaria Register.
- Comparison of relapse rates between patients receiving 22.5 mg and 30 mg of primaquine daily for 14 days.
Main Results:
- The 22.5 mg daily primaquine dose was associated with a 6.63 times higher relative risk of vivax malaria relapse compared to the 30 mg dose.
- Evidence suggests increasing tolerance to the lower primaquine dose in the studied region.
Conclusions:
- The 30 mg daily primaquine regimen is more effective in preventing vivax malaria relapses than the 22.5 mg regimen.
- Higher primaquine doses are recommended for effective treatment and prevention of vivax malaria in this region.